Followers | 37 |
Posts | 3805 |
Boards Moderated | 0 |
Alias Born | 07/08/2002 |
Monday, February 23, 2015 9:17:51 AM
Company checkpoints
By Stephen Parmley, Senior Writer
Published on Thursday, January 29, 2015
The spate of biotechs announcing new targets, combinations or milestones in the PD-1space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of checkpoint inhibitors. While AnaptysBio Inc. and cCAM have preclinical targets that could complement PD-1 inhibition, OncoSec Medical Inc. is about to enter the clinic with a combination that uses PD-1 suppression to potentiate the immune activation of IL-12.
The push for new compounds is driven by the fact that many patients don't respond to PD-1 therapies because their tumors have either low or no expression of the receptor's ligand, PD-L1. By acting through complementary pathways, upregulating the expression of PD-L1 or increasing the ability of antigen-presenting cells to trigger immune pathways, the next generation of compounds is designed to potentiate the tumor-killing effect of PD-1 inhibitors (See Cover Story).
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM